Common Stock, par value $0.001 per share
- Symbol
- TXMD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
TherapeuticsMD, Inc.
TXMDNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02 Results of Operations and Financial Condition. The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.
Press release in this filing
TherapeuticsMD Announces Second Quarter 2026 Financial Results →Company context
TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.
Current securities
Recent company filings
- 10-Q filingAug 11, 2026
- SCHEDULE 13G/A - filed by Baselake Partners, LP regarding TherapeuticsMD, Inc.Aug 5, 2026
- 10-Q filingMay 12, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureMay 12, 2026
- SCHEDULE 13G - filed by Baselake Partners, LP regarding TherapeuticsMD, Inc.Apr 6, 2026
Registered securities in this filing
THERAPEUTICSMD, INC. · 8-K · Filed 2026-08-11
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial
Condition.
The information provided in Item 7.01 of this
Current Report on Form 8-K is incorporated in this Item 2.02 by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 11, 2026, TherapeuticsMD, Inc.,
a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended June
30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
The information in this Item 7.01 and the information
contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general
incorporation language in the filing.
The Company does not have, and expressly disclaims,
any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances
on which any forward-looking statement is based.
Filed exhibits (1)
EX-99.1 2 ea029897901ex99-1.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 11, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS." Exhibit 99.1 FOR IMMEDIATE RELEASE TherapeuticsMD Announces Second Quarter 2026 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Company recorded $869 thousand in license revenue for the second quarter of 2026, compared to $952 thousand in license revenue for the second quarter of 2025. The decrease is attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses were $1.7 million, an increase of $38 thousand, or 2.3%, compared to $1.…
Open exhibit ↗